Oncology Central

FDA approves first and only treatment for advanced cutaneous squamous cell carcinoma

The US FDA has approved Libtayo® (cemiplimab-rwlc), the first and only treatment specifically approved and available for advanced cutaneous squamous cell carcinoma (CSCC) in the USA.

CSCC is the second most common form of skin cancer and is responsible for an estimated 7000 deaths each year in the USA. It currently accounts for approximately 20% of all skin cancers in the USA, with the number of newly diagnosed cases expected to rise annually. Libtayo is the third anti-PD-1 approved in the USA.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.